An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Temozolomide Treatment in Patients With Invasive Pituitary Tumors.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Temozolomide (Primary)
- Indications Pituitary cancer
- Focus Therapeutic Use
- 31 Jul 2020 Biomarkers information updated
- 09 Sep 2011 Planned end date changed from 1 Dec 2011 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 09 Sep 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.